In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopharma Quarterly Deal-Making Statistics, Q1 2017

A look at financing, M&A and alliance activity January–March 2017

Executive Summary

Biopharma financing decreased by 29% in the first quarter of 2017; conversely, M&As set a record, reaching $61.9 billion. The largest alliance of the quarter involved the microbiome.

Advertisement

Related Content

Brigatinib Approval Validates Ariad Buy, But Can Takeda Carve A Position?
Scrip Asks… Is The Microbiome Hype Or Happening?
Acquired Stada To Act As 'Core' For Future Bain and Cinven Bolt-Ons
Siliq Probably Isn't The Light At The End Of Valeant's Tunnel
Is Takeda's Consumer Unit 'Agile' Enough To Stretch Outside Japan?
Gilead, With Two PRVs In Hand, Holds Options For Accelerating Late-Stage Pipeline
Reckitt Expands 'OTC' Business, China Presence With Mead Johnson
J&J’s $30bn For Actelion Buys Immediate And Longer-Term Value
Lilly Pays Nearly $1bn To Regain Migraine Candidate It Once Sold For $1m
Takeda Acquires Ariad In $5.2bn Deal – US Infrastructure A Key Component?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV005096

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel